Summary

EudraCT Number: 2009-012201-19

Sponsor's Protocol Code Number: EX2211-3748

National Competent Authority: Austria - BASG

Clinical Trial Type: EEA CTA

Trial Status: Completed

Date on which this record was first entered in the EudraCT database: 2010-06-08

Link: https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-012201-19/AT/

A. Protocol Information

A.1 Member State Concerned: Austria - BASG

A.2 EudraCT number: 2009-012201-19

A.3 Full title of the trial: LEADER

Liraglutide Effect and Action in Diabetes:

Evaluation of cardiovascular outcome Results

A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events

A.3.1 Title of the trial for lay people, in easily understood, i.e. non-technical, language: LEADER

Liraglutide Effect and Action in Diabetes:

Evaluation of cardiovascular outcome Results

A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events

A.3.2 Name or abbreviated title of the trial where available: LEADER®

A.4.1 Sponsor's protocol code number: EX2211-3748

A.7 Trial is part of a Paediatric Investigation Plan: Information not present in EudraCT

A.8 EMA Decision number of Paediatric Investigation Plan:

B. Sponsor Information

Sponsor 1

B.1.1 Name of Sponsor: Novo Nordisk A/S

B.1.3.4 Country: Denmark

B.3.1 and B.3.2 Status of the sponsor: Commercial

B.4 Source(s) of Monetary or Material Support for the clinical trial:

B.4.1 Name of organisation providing support:

B.4.2 Country:

B.5 Contact point designated by the sponsor for further information on the trial

B.5.1 Name of organisation:

B.5.2 Functional name of contact point:

D. IMP Identification

D.IMP: 1

D.1.2 and D.1.3 IMP Role: Test

D.2 Status of the IMP to be used in the clinical trial

D.2.1 IMP to be used in the trial has a marketing authorisation: Yes

D.2.1.1.1 Trade name: Victoza®

D.2.1.1.2 Name of the Marketing Authorisation holder: Novo Nordisk A/S

D.2.1.2 Country which granted the Marketing Authorisation: European Union

D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No

D.2.5.1 Orphan drug designation number:

D.3 Description of the IMP

D.3.1 Product name: Victoza®

D.3.4 Pharmaceutical form: Solution for injection

D.3.4.1 Specific paediatric formulation: Information not present in EudraCT

D.3.7 Routes of administration for this IMP:

Subcutaneous use

D.3.8 to D.3.10 IMP Identification Details (Active Substances)

D.3.8 INN - Proposed INN: Liraglutide

D.3.9.1 CAS number: 204656-20-2

D.3.10 Strength

D.3.10.1 Concentration unit: mg/ml milligram(s)/millilitre

D.3.10.2 Concentration type: equal

D.3.10.3 Concentration number: 6.0

D.3.11 The IMP contains an

D.3.11.1 Active substance of chemical origin: No

D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): Yes

D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT

D.3.11.3.1 Somatic cell therapy medicinal product: No

D.3.11.3.2 Gene therapy medical product: No

D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT

D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT

D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT

D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT

D.3.11.5 Radiopharmaceutical medicinal product: No

D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No

D.3.11.7 Plasma derived medicinal product: No

D.3.11.8 Extractive medicinal product: No

D.3.11.9 Recombinant medicinal product: Yes

D.3.11.10 Medicinal product containing genetically modified organisms: No

D.3.11.11 Herbal medicinal product: No

D.3.11.12 Homeopathic medicinal product: No

D.3.11.13 Another type of medicinal product: No

D.8 Information on Placebo

D.8 Placebo: 1

D.8.1 Is a Placebo used in this Trial? Yes

D.8.3 Pharmaceutical form of the placebo: Solution for injection

D.8.4 Route of administration of the placebo: Subcutaneous use

E. General Information on the Trial

E.1 Medical condition or disease under investigation

E.1.1 Medical condition(s) being investigated: Type 2 diabetes mellitus

MedDRA Classification

E.1.2 Medical condition or disease under investigation:

E.1.2 Version: 17.0

E.1.2 Level: PT

E.1.2 Classification code: 10067585

E.1.2 Term: Type 2 diabetes mellitus

E.1.2 System Organ Class: 10027433 - Metabolism and nutrition disorders

E.1.3 Condition being studied is a rare disease: No

E.2 Objective of the trial

E.2.1 Main objective of the trial: To assess the effect of treatment with liraglutide compared to placebo for at least 3.5 year and up to 5 years on the incidence of cardiovascular events, as defined by the below primary and secondary endpoints, in adults with type 2 diabetes that are at high risk for cardiovascular events

E.2.2 Secondary objectives of the trial: To assess the efficacy and safety with regard to clinically important events or other surrogate parameters of treatment with liraglutide compared to placebo in adults with type 2 diabetes that are at high risk for cardiovascular events

E.2.3 Trial contains a sub-study: No

E.3 Principal inclusion criteria: • Men or women with type 2 diabetes

• Age ≥ 50 years at screening and concomitant cardiovascular, cerebrovascular or peripheral vascular disease or chronic renal failure or chronic heart failure OR age ≥ 60 years at screening and other specified risk factors of vascular disease

• HbA1c ≥ 7.0% at screening

E.4 Principal exclusion criteria: • Type 1 diabetes

• Use of a GLP-1 receptor agonist (exenatide, liraglutide or other) or pramlintide or any (dipeptidyl peptidase 4 (DPP-4) inhibitor within the 3 months prior to screening

• Use of insulin other than human NPH insulin or long-acting insulin analogue or premixed insulin within 3 months prior to screening. Short-term use of other insulin during this period in connection with intercurrent illness is allowed, at Investigators discretion

• Acute decompensation of glycaemic control requiring immediate intensification of treatment to prevent acute complications of diabetes (e.g., diabetic ketoacidosis) in the previous 3 months

• An acute coronary or cerebrovascular event in the previous 14 days

• Current continuous renal replacement therapy

• End-stage liver disease

• Chronic heart failure NYHA IV

• A prior solid organ transplant or awaiting solid organ transplant

• Family or personal history of multiple endocrine neoplasia type 2 (MEN2) or familial

medullary thyroid carcinoma (FMTC)

• Personal history of non-familial medullary thyroid carcinoma

• Malignant neoplasm requiring chemotherapy, surgery, radiation or palliative therapy in the previous 5 years. Subjects with intraepithelial squamous cell carcinoma of the skin (Bowen’s disease) treated with topical 5-fluorouracil (5FU) and subjects with basal cell skin cancer are allowed to enter the trial

E.5 End points

E.5.1 Primary end point(s): Time from randomisation to first occurrence of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke (a composite cardiovascular outcome)

E.6 and E.7 Scope of the trial

E.6 Scope of the Trial

E.6.1 Diagnosis: No

E.6.2 Prophylaxis: No

E.6.3 Therapy: No

E.6.4 Safety: Yes

E.6.5 Efficacy: Yes

E.6.6 Pharmacokinetic: No

E.6.7 Pharmacodynamic: No

E.6.8 Bioequivalence: No

E.6.9 Dose response: No

E.6.10 Pharmacogenetic: No

E.6.11 Pharmacogenomic: No

E.6.12 Pharmacoeconomic: No

E.6.13 Others: No

E.7 Trial type and phase

E.7.1 Human pharmacology (Phase I): No

E.7.1.1 First administration to humans: No

E.7.1.2 Bioequivalence study: No

E.7.1.3 Other: No

E.7.1.3.1 Other trial type description:

E.7.2 Therapeutic exploratory (Phase II): No

E.7.3 Therapeutic confirmatory (Phase III): Yes

E.7.4 Therapeutic use (Phase IV): No

E.8 Design of the trial

E.8.1 Controlled: Yes

E.8.1.1 Randomised: Yes

E.8.1.2 Open: No

E.8.1.3 Single blind: No

E.8.1.4 Double blind: Yes

E.8.1.5 Parallel group: Yes

E.8.1.6 Cross over: No

E.8.1.7 Other: Yes

E.8.1.7.1 Other trial design description: Run-in period is open label

E.8.2 Comparator of controlled trial

E.8.2.1 Other medicinal product(s): No

E.8.2.2 Placebo: Yes

E.8.2.3 Other: No

E.8.3 The trial involves single site in the Member State concerned: No

E.8.4 The trial involves multiple sites in the Member State concerned: Yes

E.8.4.1 Number of sites anticipated in Member State concerned: 5

E.8.5 The trial involves multiple Member States: Yes

E.8.5.1 Number of sites anticipated in the EEA: 133

E.8.6 Trial involving sites outside the EEA

E.8.6.1 Trial being conducted both within and outside the EEA: Yes

E.8.6.2 Trial being conducted completely outside of the EEA: Information not present in EudraCT

E.8.6.3 If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned:

E.8.7 Trial has a data monitoring committee: Yes

E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial: Not applicable

E.8.9 Initial estimate of the duration of the trial

E.8.9.1 In the Member State concerned years:

E.8.9.1 In the Member State concerned months:

E.8.9.1 In the Member State concerned days:

E.8.9.2 In all countries concerned by the trial years: 5

E.8.9.2 In all countries concerned by the trial months: 2

E.8.9.2 In all countries concerned by the trial days: 29

F. Population of Trial Subjects

F.1 Age Range

F.1.1 Trial has subjects under 18: No

F.1.1.1 In Utero: No

F.1.1.2 Preterm newborn infants (up to gestational age < 37 weeks): No

F.1.1.3 Newborns (0-27 days): No

F.1.1.4 Infants and toddlers (28 days-23 months): No

F.1.1.5 Children (2-11years): No

F.1.1.6 Adolescents (12-17 years): No

F.1.2 Adults (18-64 years): Yes

F.1.3 Elderly (>=65 years): Yes

F.2 Gender

F.2.1 Female: Yes

F.2.2 Male: Yes

F.3 Group of trial subjects

F.3.1 Healthy volunteers: No

F.3.2 Patients: Yes

F.3.3 Specific vulnerable populations: Yes

F.3.3.1 Women of childbearing potential not using contraception : No

F.3.3.2 Women of child-bearing potential using contraception: Yes

F.3.3.3 Pregnant women: No

F.3.3.4 Nursing women: No

F.3.3.5 Emergency situation: No

F.3.3.6 Subjects incapable of giving consent personally: No

F.3.3.7 Others: No

F.4 Planned number of subjects to be included

F.4.1 In the member state: 119

F.4.2 For a multinational trial

F.4.2.1 In the EEA: 3000

F.4.2.2 In the whole clinical trial: 8754

F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition): Not applicable

G. Investigator Networks to be involved in the Trial

N. Review by the Competent Authority or Ethics Committee in the country concerned

N. Competent Authority Decision: Authorised

N. Date of Competent Authority Decision: 2010-07-02

N. Ethics Committee Opinion of the trial application: Favourable

N. Ethics Committee Opinion: Reason(s) for unfavourable opinion:

N. Date of Ethics Committee Opinion: 2010-07-02

P. End of Trial

P. End of Trial Status: Completed

P. Date of the global end of the trial: 2015-12-17